Liposomal N-acylethanolamine-hydrolyzing acid amidase (NAAA) inhibitor F96 as a new therapy for colitis

Despite numerous advances in the pathological mechanism of inflammatory bowel disease (IBDs), the ideal therapy is still missing. N-Acylethanolamine-hydrolyzing acid amidase (NAAA), a cysteine hydrolase that deactivates fatty acid ethanolamides, has been recognized as a new therapeutic target for IB...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiu, Yangyan, Wang, Kaizhen, Chen, Jingfang, Zhuo, Zhiqiang, Xiu, Yanghui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society of Chemistry 2020
Materias:
Chemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9056838/
https://www.ncbi.nlm.nih.gov/pubmed/35519029
http://dx.doi.org/10.1039/d0ra05264g

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9056838/
https://www.ncbi.nlm.nih.gov/pubmed/35519029
http://dx.doi.org/10.1039/d0ra05264g

Ejemplares similares